Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5077459 | 0.97 | KDM4E (0.40) | CA12CA6CA7CA9CA14 | |
| SCHEMBL9345163 | 0.87 | ALDH1A1 (0.33) | CA12CA6CA7CA9CA14 | |
| SCHEMBL2890159 | 0.87 | CA12 (0.55) | CA12CA6CA7CA9CA14 | |
| SCHEMBL18756474 | 0.85 | — | — | |
| SCHEMBL39229 | 0.81 | CA12 (0.43) | CA12CA6CA7CA9CA14 | |
| SCHEMBL5070970 | 0.81 | — | — | |
| SCHEMBL12940281 | 0.81 | — | — | |
| SCHEMBL11082785 | 0.81 | DNM1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11085765 | 0.81 | DNM1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL9847180 | 0.81 | DNM1 (0.44) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452057-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | Tricida Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| CN-109414453-A | composition for treating acid-base imbalance | 特里赛达公司 | 2019-03-01 | — | — | CN | claimed |
| WO-2017193050-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | TRICIDA, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| EP-3003327-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014197725-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA, INC. (US) | 2014-12-11 | — | — | WO | claimed |
| EP-4565559-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | Philera New Zealand Ltd. (NZ) | 2025-06-11 | — | — | EP | disclosed |
| US-12076340-B2 | Use of trientine to deliver copper to ischemic tissue | INNOLIFE CO., LTD. (CN) | 2024-09-03 | — | — | US | disclosed |
| WO-2024033786-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | PHILERA NEW ZEALAND LTD. (NZ) | 2024-02-15 | — | — | WO | disclosed |
| US-20240043370-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | PHILERA NEW ZEALAND LTD. (NZ) | 2024-02-08 | — | — | US | disclosed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | disclosed |
| US-20210379102-A1 | USE OF TRIENTINE TO DELIVER COPPER TO ISCHEMIC TISSUE | INNOLIFE CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-11033579-B2 | Use of trientine to deliver copper to ischemic tissue | INNOLIFE CO., LTD. (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-1778618-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | Protemix Corporation Limited (NZ) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007021960-A2 | POLYMER COMPOSITIONS AND PROCESSES FOR MAKING AND USING SAME | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006027705-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORPORATION LIMITED (NZ) | 2006-03-16 | — | — | WO | disclosed |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PHILERA NEW ZEALAND LIMITED (NZ) | 2006-02-23 | — | — | US | disclosed |
| US-20030232799-A1 | Copper chelators for treating ocular Inflammation | LI, NING, DR. (CN) | 2003-12-18 | — | — | US | disclosed |
| EP-1370254-A2 | COPPER CHELATORS FOR TREATING OCULAR INFLAMMATION | The University of British Columbia (CA) | 2003-12-17 | — | — | EP | disclosed |
| US-20030055113-A1 | Copper chelators for treating ocular inflammation | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2003-03-20 | — | — | US | disclosed |
| WO-2002043722-A2 | COPPER CHELATORS FOR TREATING OCULAR INFLAMMATION | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795150-B2 | Synthesis of triethylenetetramines | PNMT, TES, TPR | CA12 3847/4885CA6 3825/4885CA7 3796/4885 |
| US-11033579-B2 | Use of trientine to deliver copper to ischemic tissue | HIF1A, HIF1AN, P4HA1 | CA12 2827/4885CA6 1021/4885CA7 1503/4885 |
| US-12076340-B2 | Use of trientine to deliver copper to ischemic tissue | HIF1A, HIF1AN, P4HA1 | CA12 2827/4885CA6 1021/4885CA7 1503/4885 |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | TET1, TET2, TET3 | CA12 1751/4885CA6 1620/4885CA7 1363/4885 |
| US-20210379102-A1 | USE OF TRIENTINE TO DELIVER COPPER TO ISCHEMIC TISSUE | HIF1A, HIF1AN, P4HA1 | CA12 2827/4885CA6 1021/4885CA7 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.